Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia
- PMID: 34380072
- DOI: 10.1016/j.hrthm.2021.08.004
Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia
Abstract
Background: Ventricular tachycardia (VT) is a potentially lethal complication of structural heart disease. Despite optimal management, a subgroup of patients continue to suffer from recurrent VT. Recently, cardiac stereotactic body radiotherapy (CSBRT) has been introduced as a treatment option in patients with VT refractory to antiarrhythmic drugs and catheter ablation.
Objective: The purpose of this study was to establish an expert consensus regarding the conduct and use of CSBRT for refractory VT.
Methods: We conducted a modified Delphi process. Thirteen experts from institutions from Germany and Switzerland participated in the modified Delphi process. Statements regarding the following topics were generated: treatment setting, institutional expertise and technical requirements, patient selection, target volume definition, and monitoring during and after CSBRT. Agreement was rated on a 5-point Likert scale. The strength of agreement was classified as strong agreement (≥80%), moderate agreement (≥66%) or no agreement (<66%).
Results: There was strong agreement regarding the experimental status of the procedure and the preference for treatment in clinical trials. CSBRT should be conducted at specialized centers with a strong expertise in the management of patients with ventricular arrhythmias and in stereotactic body radiotherapy for moving targets. CSBRT should be restricted to patients with refractory VT with optimal antiarrhythmic medication who underwent prior catheter ablation or have contraindications. Target volume delineation for CSBRT is complex. Therefore, interdisciplinary processes that should include cardiology/electrophysiology and radiation oncology as well as medical physics, radiology, and nuclear medicine are needed. Optimal follow-up is required.
Conclusion: Prospective trials and pooled registries are needed to gain further insight into this promising treatment option for patients with refractory VT.
Keywords: Electrical storm; Radioablation; Stereotactic radiotherapy; Structural heart disease; Ventricular tachycardia.
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Comment in
-
Cardiac stereotactic radiation therapy: Charting a course through unchartered waters.Heart Rhythm. 2021 Dec;18(12):2146-2147. doi: 10.1016/j.hrthm.2021.08.014. Epub 2021 Aug 18. Heart Rhythm. 2021. PMID: 34418542 No abstract available.
Similar articles
-
Stereotactic arrhythmia radioablation for refractory scar-related ventricular tachycardia.Heart Rhythm. 2020 Aug;17(8):1241-1248. doi: 10.1016/j.hrthm.2020.02.036. Epub 2020 Mar 6. Heart Rhythm. 2020. PMID: 32151737
-
Stereotactic body radiotherapy for ventricular tachycardia (cardiac radiosurgery) : First-in-patient treatment in Germany.Strahlenther Onkol. 2020 Jan;196(1):23-30. doi: 10.1007/s00066-019-01530-w. Epub 2019 Oct 31. Strahlenther Onkol. 2020. PMID: 31673718
-
Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia.Circulation. 2019 Jan 15;139(3):313-321. doi: 10.1161/CIRCULATIONAHA.118.038261. Circulation. 2019. PMID: 30586734 Free PMC article. Clinical Trial.
-
Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.Curr Cardiol Rep. 2017 Sep 13;19(11):105. doi: 10.1007/s11886-017-0924-0. Curr Cardiol Rep. 2017. PMID: 28900864 Review.
-
[Refractory ventricular tachycardia: Is there a role for radiotherapy?].Cancer Radiother. 2020 Oct;24(6-7):534-546. doi: 10.1016/j.canrad.2020.06.005. Epub 2020 Aug 10. Cancer Radiother. 2020. PMID: 32792297 Review. French.
Cited by
-
Stereotactic Arrhythmia Radioablation Treatment of Ventricular Tachycardia: Current Technology and Evolving Indications.J Cardiovasc Dev Dis. 2023 Apr 17;10(4):172. doi: 10.3390/jcdd10040172. J Cardiovasc Dev Dis. 2023. PMID: 37103051 Free PMC article. Review.
-
Stereotactic arrhythmia radioablation and its implications for modern cardiac electrophysiology: results of an EHRA survey.Europace. 2024 May 2;26(5):euae110. doi: 10.1093/europace/euae110. Europace. 2024. PMID: 38666444 Free PMC article.
-
Institutional experience report on the target contouring workflow in the radiotherapy department for stereotactic arrhythmia radioablation delivered on conventional linear accelerators.Strahlenther Onkol. 2024 Jan;200(1):83-96. doi: 10.1007/s00066-023-02159-6. Epub 2023 Oct 23. Strahlenther Onkol. 2024. PMID: 37872398
-
Patient vulnerability in stereotactic arrhythmia radioablation (STAR): a preliminary ethical appraisal from the STOPSTORM.eu consortium.Strahlenther Onkol. 2024 Oct;200(10):903-907. doi: 10.1007/s00066-024-02230-w. Epub 2024 Apr 23. Strahlenther Onkol. 2024. PMID: 38652131 Free PMC article.
-
Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.Front Oncol. 2024 Jul 8;14:1399589. doi: 10.3389/fonc.2024.1399589. eCollection 2024. Front Oncol. 2024. PMID: 39040445 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical